Staar Surgical Co. Stock
Staar Surgical Co. Stock
Staar Surgical Co. gained 0.970% compared to yesterday.
We see a rather positive sentiment for Staar Surgical Co. with 11 Buy predictions and 1 Sell predictions.
As a result the target price of 49 € shows a slightly positive potential of 14.78% compared to the current price of 42.69 € for Staar Surgical Co..
Pros and Cons of Staar Surgical Co. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Staar Surgical Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Staar Surgical Co. | 0.970% | -3.460% | -4.986% | -30.108% | 47.055% | -62.321% | - |
| Orasure Tech | -0.980% | 1.000% | -8.182% | -18.548% | -32.215% | -37.854% | -42.489% |
| scPharmaceuticals | -3.170% | 1.905% | -6.550% | -58.039% | -25.565% | -11.570% | - |
| SI-BONE Inc | -3.700% | -2.985% | -7.143% | -39.815% | -31.579% | -50.382% | - |
Comments
STAAR Surgical (NASDAQ: STAA) had its price target raised by analysts at Mizuho from $45.00 to $53.00. They now have a "buy" rating on the stock.
Show more
Ratings data for STAA provided by MarketBeat
STAAR Surgical (NASDAQ: STAA) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Show more
Ratings data for STAA provided by MarketBeat
STAAR Surgical (NASDAQ: STAA) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $50.00 price target on the stock.
Show more
Ratings data for STAA provided by MarketBeat
News
STAAR Surgical Reports First Quarter 2024 Results
STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical to Report First Quarter Results on May 7, 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today